drugset / Trial / NCT00097383

Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer

NCT00097383

Phase 1/2 Completed Eli Lilly and Company
Non-randomizedTreatment

Summary

This is a non-randomized Phase 2 portion of a study testing ALIMTA and epirubicin in combination for locally advanced or metastatic breast cancer. Epirubicin is a well-established drug for the therapy of breast cancer. Both ALIMTA and epirubicin have been combined with other drugs but they have not yet been combined with each other. It is expected that the patient will benefit from the different mechanisms of action of the two drugs.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Epirubicin Small molecule
Subject Pemetrexed Small molecule

Indications